Isbogrel

Drug Profile

Isbogrel

Alternative Names: Antexan; CV 4151

Latest Information Update: 09 Nov 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Anti-ischaemics; Antiplatelets; Ischaemic heart disorder therapies; Monounsaturated fatty acids; Pyridines; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias; Thrombosis; Transient ischaemic attacks

Most Recent Events

  • 09 Nov 2000 Discontinued-preregistration for Transient ischaemic attacks in Japan (Unknown route)
  • 08 Nov 2000 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)
  • 08 Nov 2000 Investigation in Thrombosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top